SCHEDULE: Calidi Biotherapeutics: Ognian Gavrilov Discloses 7.78% Stake

Ognian Anguelov Gavrilov has disclosed a 7.78% beneficial ownership stake in Calidi Biotherapeutics, Inc., a filing that was submitted late due to an inadvertent oversight.

Summary

• Ognian Anguelov Gavrilov beneficially owns 560,000 shares of Calidi Biotherapeutics, Inc. common stock.
• This ownership represents 7.78% of the company's outstanding common stock.
• Gavrilov holds sole voting power and sole dispositive power over all 560,000 shares.
• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
• This Schedule 13G is a first-time filing and was submitted late due to an inadvertent oversight.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development due to a significant individual stake, tempered by the negative aspect of a late regulatory filing.

Positives

• A significant individual investor, Ognian Anguelov Gavrilov, has taken a substantial 7.78% stake in Calidi Biotherapeutics, Inc., indicating confidence in the company's prospects.
• The filing explicitly states that the shares are not held for the purpose of changing or influencing control, suggesting a passive, long-term investment intent.

Negatives

• The Schedule 13G filing was submitted late due to an inadvertent oversight, which represents a compliance lapse by the reporting person.

Risks

• The late filing of this Schedule 13G indicates a potential compliance oversight by the reporting person, which could raise questions about adherence to regulatory requirements.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant individual investor stakes, particularly in the biotechnology sector, can signal confidence in a company's long-term potential, especially for firms like Calidi Biotherapeutics that are often in early-stage development or clinical trials. Such filings are routinely monitored by the market for shifts in institutional or influential individual ownership.

Stakeholder Impact

• Shareholders may view the significant stake by an individual investor as a positive signal of confidence in Calidi Biotherapeutics' future prospects.
• Regulatory bodies may scrutinize the late filing for compliance adherence, though the impact on the company itself is indirect as it pertains to the reporting person.

Key Dates

Recommendation

The disclosure of a significant individual stake by Ognian Anguelov Gavrilov in Calidi Biotherapeutics is a positive signal of investor confidence, suggesting a belief in the company's long-term value. However, the late filing due to an oversight introduces a minor compliance concern for the reporting person. Given the passive nature of the stake and the absence of other material operational or financial updates, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future developments and the company's core business performance.

Keywords

Calidi Biotherapeutics, Ognian Anguelov Gavrilov, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, SEC Filing, Shareholder Stake